Authorized purpose: VisiRad XR is a computer-aided detection device that identifies and marks regions of interest suspicious for lung nodules and masses measuring 6-60 mm on chest radiographs in patients older than 21 years in outpatient or emergency-department settings.
Clinical role
Processing, measurement, marking, or planning support for labeled projection X-ray images.
Images and patients
X-ray/Radiography · Adult chest and pulmonary nodules or masses 6-60 mm
Key limitation
Keep in mind: Output is an aid and does not replace review of source images, clinical judgment, or the labeled standard of care; patient, view, size, and anatomy limits apply.
Clinical detailsPurpose, workflow fit, evidence, and safety record
Workflow navigation pilot
Workflow role has not yet been reviewed for this navigation pilot.
A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources
What does this software do?Authorized purpose: VisiRad XR is a computer-aided detection device that identifies and marks regions of interest suspicious for lung nodules and masses measuring 6-60 mm on chest radiographs in patients older than 21 years in outpatient or emergency-department settings.
Which images or clinical context are in scope?Modality: X-ray/Radiography Anatomy or clinical context: Adult chest and pulmonary nodules or masses 6-60 mm Input: Supported 2D X-ray or radiographic images and user inputs from the exact labeled acquisition workflow.
Who uses it?Intended users: Qualified physicians and trained radiology or orthopedic professionals within the labeled workflow.
What does the software produce?Output: Marks, landmarks, measurements, or planning views for professional review.
What is its most important limitation?Key limitation: Output is an aid and does not replace review of source images, clinical judgment, or the labeled standard of care; patient, view, size, and anatomy limits apply.
Clinical takeaway. Clinical role: VisiRad XR is a computer-aided detection device that identifies and marks regions of interest suspicious for lung nodules and masses measuring 6-60 mm on chest radiographs in patients older than 21 years in outpatient or emergency-department settings.
Evidence takeaway. Evidence from the reviewed source record: The exact FDA document reports a standalone test (NLST plus two independent data sites): image-level sensitivity 0.83 (95% CI: 0.81-0.84) with 1.5 average false positives per image; AUC 0.73 (95% CI: 0.71-0.74). A retrospective reader study (24 readers, 600 images, two sites) showed average AUC improvement of 0.035 (95% CI: 0.021, 0.048) at Site I and 0.018 (95% CI: 0.005, 0.031) at Site II; average reader sensitivity increased by 0.076 and specificity decreased by 0.086. Results are as reported in the FDA submission, not independent validation.
Evidence context
Evidence context not reviewed for this FDA record.
Public-label constraints
Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.
Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.
Purpose
VisiRad XR is a computer-aided detection device that identifies and marks regions of interest suspicious for lung nodules and masses measuring 6-60 mm on chest radiographs in patients older than 21 years in outpatient or emergency-department settings.
Output is an aid and does not replace review of source images, clinical judgment, or the labeled standard of care; patient, view, size, and anatomy limits apply.
The exact FDA document reports a standalone test (NLST plus two independent data sites): image-level sensitivity 0.83 (95% CI: 0.81-0.84) with 1.5 average false positives per image; AUC 0.73 (95% CI: 0.71-0.74). A retrospective reader study (24 readers, 600 images, two sites) showed average AUC improvement of 0.035 (95% CI: 0.021, 0.048) at Site I and 0.018 (95% CI: 0.005, 0.031) at Site II; average reader sensitivity increased by 0.076 and specificity decreased by 0.086. Results are as reported in the FDA submission, not independent validation.
Exact FDA submission
Checked 2026-11-14
Packet wording: "A standalone performance test was executed on VisiRad XR to demonstrate generalizability and performance endpoints on a broad, representative dataset. The dataset consisted of data from three sources: National Lung Screening Trials (NLST) and two independent data sites." … "The primary endpoint for the standalone performance test was device sensitivity calculated at an image level. The study was executed at a fixed operating threshold. Study results demonstrated an overall sensitivity of 0.83 (95% CI: 0.81-0.84) with average false positives per image of 1.5.". Read from the exact FDA decision document on 2026-11-14.
Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.
Evidence summary
The exact FDA document reports a standalone test (NLST plus two independent data sites): image-level sensitivity 0.83 (95% CI: 0.81-0.84) with 1.5 average false positives per image; AUC 0.73 (95% CI: 0.71-0.74). A retrospective reader study (24 readers, 600 images, two sites) showed average AUC improvement of 0.035 (95% CI: 0.021, 0.048) at Site I and 0.018 (95% CI: 0.005, 0.031) at Site II; average reader sensitivity increased by 0.076 and specificity decreased by 0.086. Results are as reported in the FDA submission, not independent validation.
FDA source
Exact FDA submission
Checked 2026-11-14
Packet wording: "A standalone performance test was executed on VisiRad XR to demonstrate generalizability and performance endpoints on a broad, representative dataset. The dataset consisted of data from three sources: National Lung Screening Trials (NLST) and two independent data sites." … "The primary endpoint for the standalone performance test was device sensitivity calculated at an image level. The study was executed at a fixed operating threshold. Study results demonstrated an overall sensitivity of 0.83 (95% CI: 0.81-0.84) with average false positives per image of 1.5.". Read from the exact FDA decision document on 2026-11-14.
Standalone image-level sensitivity for lung nodules and masses on chest radiographs (NLST and two independent data sites, fixed operating threshold): 0.83 (95% CI: 0.81-0.84), with 1.5 average false positives per image.
FDA source
Exact FDA submission
Checked 2026-11-14
Packet wording: "The primary endpoint for the standalone performance test was device sensitivity calculated at an image level. The study was executed at a fixed operating threshold. Study results demonstrated an overall sensitivity of 0.83 (95% CI: 0.81-0.84) with average false positives per image of 1.5." … "A standalone performance test was executed on VisiRad XR to demonstrate generalizability and performance endpoints on a broad, representative dataset. The dataset consisted of data from three sources: National Lung Screening Trials (NLST) and two independent data sites.". Read from the exact FDA decision document on 2026-11-14; this is the submission-reported standalone result, not independent validation.
No exact-submission and version-linked specificity endpoint is promoted; candidate or product-family values were not substituted.
No contextualized exact-version metric has completed evidence review. Regulatory-document values, when available, are shown above with their limitations.
FDA submission-specific verification and validation evidence for K223133
DesignFDA 510(k) regulatory decision material and submission-specific verification or validation evidence for K223133; this is regulatory evidence, not an independent clinical effectiveness study.
PopulationThe labeled population, anatomy, images, and test materials described in the exact FDA decision material for K223133; a broader clinical population is not established here.
Scopeexact submission
Tested versionVisiRad XR (K223133)
IndependenceSponsor or vendor study
K223133
The exact FDA material is submission-specific and should not be generalized to other versions, enabled options, sites, protocols, or clinical outcomes.
Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.
Postmarket safety review
Not established in reviewed sources
Reviewed sources checked
Exact FDA submission
Checked 2026-09-04
No native submission-identifier match was found in the checked openFDA radiology recall snapshot. Product-name, manufacturer, and adverse-event searches remain necessary; this does not establish that no recall or safety report exists.
Pricing & contractsPublic price, contract terms, and reimbursement
IT implementationDeployment, interfaces, data handling, and support
System and version relationships
Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.
No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.
Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.
Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner
No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.
Acquisition/source
Source context, not route validation: Supported 2D X-ray or radiographic images and user inputs from the exact labeled acquisition workflow.
Scope: Exact FDA submission.
Confirm scanner/model, protocol, series completeness and both software builds.
Source context, not route validation: The exact FDA package describes DICOM image input and a secondary DICOM output with annotated regions of interest, returned so that it hangs behind the primary radiograph using standard DICOM hanging protocol. Interface versions and local compatibility require confirmation.
Scope: Exact FDA submission. Packet wording: "VisiRad XR takes DICOM images as input, utilizes machine learning algorithms to detect suspicious regions and outputs a secondary DICOM with annotated regions of interest (ROIs)." … "The secondary DICOM does not overwrite or replace the primary radiograph, it is returned such that it hangs, using standard DICOM hanging protocol, behind the primary image.". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.
Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.
Source context, not route validation: The exact FDA package describes VisiRad XR as cloud-based software that operates on both AP and PA chest radiograph views and with multiple chest radiograph hardware systems. Current hosting, data flow, and commercial configuration require vendor confirmation.
Scope: Exact FDA submission. Packet wording: "VisiRad XR detects masses in addition to nodules (lesions are considered a" … "is a cloud-based software that operates on both AP and PA image views, as well as multiple chest radiograph hardware systems.". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.
Confirm processing location, queue ownership, exclusions and exact AI build.
Unresolved route: Marks, landmarks, measurements, or planning views for professional review.
Scope: Exact FDA submission.
Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.
Unresolved route: Not established for the exact route.
Scope: Scope not established.
Name the local, platform and AI supplier support owners and escalation path.
Planned local route tests
No tests below have been performed or accepted.
Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.
Local implementation checklist
Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.
The exact FDA package describes VisiRad XR as cloud-based software that operates on both AP and PA chest radiograph views and with multiple chest radiograph hardware systems. Current hosting, data flow, and commercial configuration require vendor confirmation.
Exact FDA submission
Checked 2026-11-14
Packet wording: "VisiRad XR detects masses in addition to nodules (lesions are considered a" … "is a cloud-based software that operates on both AP and PA image views, as well as multiple chest radiograph hardware systems.". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.
The exact FDA package describes DICOM image input and a secondary DICOM output with annotated regions of interest, returned so that it hangs behind the primary radiograph using standard DICOM hanging protocol. Interface versions and local compatibility require confirmation.
Exact FDA submission
Checked 2026-11-14
Packet wording: "VisiRad XR takes DICOM images as input, utilizes machine learning algorithms to detect suspicious regions and outputs a secondary DICOM with annotated regions of interest (ROIs)." … "The secondary DICOM does not overwrite or replace the primary radiograph, it is returned such that it hangs, using standard DICOM hanging protocol, behind the primary image.". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.
Current vendor material is product-family context for K223133 only; exact release, enabled options, deployment, security, interoperability, pricing, and local workflow require confirmation.
product family · checked 2026-09-04
Vendor material is not exact-release evidence unless that linkage is separately proven.
Sources & review detailsFDA identity, research record, source ledger, and history
Regulatory identity
FDA record and catalog context
The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.
This audit distinguishes completed source review from fields that have not yet been researched.
Exact FDA record reviewedStatus
2026-09-20Last searched
31Fields reviewed
13Source classes checked
0Screened PubMed leads
0Screened trial leads
0Unreviewed FDA recall leads
The refreshed discovery snapshot contains no PubMed or ClinicalTrials.gov candidates; no external evidence was promoted. The current discovery snapshot contains 0 PubMed and 0 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.
Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.
Source classes: fda ai list, fda decision summary, vendor product page, implementation documentation, reimbursement policy, peer reviewed literature, clinical trial registry, fda device recall, literature index, trial registry, pubmed, clinical trials, openfda device recall
Field review details
Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.
Public pricing: Not publicly available - checked 2026-09-04 - Exact FDA submission
No public exact-release price, license fee, subscription, contract, or implementation cost was established in this review.
Pricing model: Not yet reviewed
Setup and integration fees: Not yet reviewed
Recurring fees: Not yet reviewed
Minimum commitment: Not yet reviewed
Contract duration: Not yet reviewed
Renewal terms: Not yet reviewed
Cancellation terms: Not yet reviewed
Support and service terms: Not yet reviewed
Trial or pilot terms: Not yet reviewed
Reimbursement: Not applicable - checked 2026-09-04 - Not applicable
CMS coverage-index context was checked, but no product-specific coverage or reimbursement determination is inferred.
Data hosting location: Not yet reviewed
Data retention: Not yet reviewed
Documented data use: Not yet reviewed
Hardware requirements: Not yet reviewed
Network requirements: Not yet reviewed
Identity and access: Not yet reviewed
Security: Not publicly available - checked 2026-09-04 - Exact FDA submission
Public sources reviewed here do not establish the complete exact-release security posture, including identity, audit, encryption, retention, remote access, vulnerability management, backup, or incident response.
Installation timeline: Not yet reviewed
Training: Not verified - checked 2026-10-27 - Exact FDA submission
Current training prerequisites, competency checks, and support commitments for the exact configuration require vendor confirmation.
Monitoring: Not verified - checked 2026-10-27 - Exact FDA submission
Current drift, quality, uptime, alert, escalation, and incident-response commitments for the exact configuration require vendor confirmation.
Authorized purpose: RAPIDSCREEN RS-2000 is a PMA-authorized computer-aided detection device that identifies and marks regions of interest on digitized frontal chest radiographs associated with solitary pulmonary nodules 9-30 mm, as an aid after the physician's initial interpretation.
Authorized purpose: Concurrent-read CADe to assist dentists in detecting specified tooth and jaw anatomy, bone-level landmarks, and root-canal-treated teeth in digital radiographs of permanent teeth in patients 15 years or older.
Modality
X-ray/Radiography
Anatomy
Permanent teeth and jaw/maxillofacial anatomy, including enamel, dentine, pulp, root, mental foramen, inferior alveolar canal, maxillary sinus, cementoenamel junction, crestal bone, and root-canal-treated teeth
Authorized purpose: Analyze frontal chest and abdominal X-ray images to detect and localize a nasally or orally inserted enteric tube, its tip and side port if present, and the diaphragm and airways for radiologist review.
Modality
X-ray/Radiography
Anatomy
Chest/lung and abdomen/stomach; enteric tube, tube tip and side port, diaphragm, and airways including carina and left/right bronchi
Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.
Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.
Accepted repository change history
No entry has been added to this scoped change history for this record. This is not proof that the record never changed.